Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Rhea-AI Summary
Day One Biopharmaceuticals (Nasdaq: DAWN) will report fourth-quarter and full-year 2025 financial results on Tuesday, February 24, 2026 at 4:30 p.m. ET. The company will host a live conference call and webcast to discuss results and corporate progress.
Live audio will be accessible via the Events section of Day One's Media & Investors page, and an archived replay will be available for 30 days following the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DAWN is up 2.72% ahead of its earnings date while close peers show mixed moves: AVBP down 2.28%, TNGX up 2.55%, KURA up 0.13%, PRAX up 0.57%, VIR up 1.25%. With no peers in the momentum scanner, the move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 11 | Revenue & guidance | Positive | +26.7% | Preliminary 2025 OJEMDA revenue, strong YoY growth, and 2026 guidance. |
| Jan 06 | Acquisition close | Positive | +1.1% | Completion of Mersana acquisition with cash and CVR consideration. |
| Dec 16 | Conference presentation | Neutral | -0.2% | Announcement of CEO presentation at J.P. Morgan Healthcare Conference. |
| Nov 24 | Clinical data update | Positive | +4.2% | Three-year follow-up Phase 2 FIREFLY-1 data for OJEMDA in pLGG. |
| Nov 18 | Conference participation | Neutral | -3.0% | Planned fireside chat at the Piper Sandler Healthcare Conference. |
Fundamental catalysts like revenue updates, guidance, acquisitions, and clinical data have historically drawn positive reactions, while conference participation headlines have seen muted or slightly negative moves.
Over the last few months, DAWN has reported strong OJEMDA growth, with preliminary 2025 net product revenue and 2026 guidance driving a 26.73% move after the Jan 11 update. The completed Mersana acquisition on Jan 6, 2026 added an ADC program and coincided with a modest gain. Clinical data from FIREFLY-1 on Nov 24, 2025 also supported a positive reaction. In contrast, conference participation updates in late 2025 drew small, mixed price changes, suggesting investors focus more on tangible financial and clinical milestones than on event logistics like today’s earnings-date announcement.
Market Pulse Summary
This announcement sets the timeline for DAWN’s detailed fourth-quarter and full-year 2025 results on February 24, 2026. It follows preliminary OJEMDA revenue and guidance, the Mersana acquisition, and encouraging FIREFLY-1 data, which previously drew constructive market reactions. Investors may focus on how finalized numbers compare with earlier estimates and on updated milestones for the expanded pipeline, using the call to refine views on growth, cash usage, and execution risk.
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025.
Live audio of the webcast will be accessible by visiting the Events section of Day One’s Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer - regardless of age - starting from day one.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301, and following the recently announced acquisition of Mersana Therapeutics, Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
DAY ONE MEDIA
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One (DAWN) report Q4 and full-year 2025 results?
How can investors access the Day One (DAWN) earnings webcast on February 24, 2026?
Will Day One (DAWN) provide an archived replay of the February 24, 2026 webcast?
What will Day One (DAWN) discuss during the February 24, 2026 conference call?
Is live audio the only way to listen to Day One's (DAWN) February 24, 2026 presentation?
